drugset
Drugs / ALX-0171
last change May 2020 re-read 3 minutes ago

ALX-0171

also known as Gontivimab

Protein / enzyme biologic

Developed for
respiratory syncytial virus infectious disease
Investigated by
Ablynx, a Sanofi company

Trials 7

today NCT03468829 · Ph 2 NCT03418571 · Ph 2 NCT02979431 · Ph 2 NCT02309320 · Ph 1/2 NCT01909843 · Ph 1 NCT01875926 · Ph 1 NCT01483911 · Ph 1
2012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 13 trials
Phase 1 NCT01909843 Jul → Dec 2013 respiratory syncytial virus infectious disease Ablynx, a Sanofi company Completed No outcome recorded
Phase 1 NCT01875926 May → Oct 2013 respiratory syncytial virus infectious disease Ablynx, a Sanofi company Completed No outcome recorded
Phase 1 NCT01483911 Nov 2011 → May 2012 respiratory syncytial virus infectious disease Ablynx, a Sanofi company Completed No outcome recorded
Phase 1/21 trial
Phase 1/2 NCT02309320 Dec 2014 → Feb 2016 respiratory syncytial virus infectious disease Ablynx, a Sanofi company Completed No outcome recorded
Phase 23 trials · 1 met primary
Phase 2 NCT03468829 Feb 2019 → May 2020 respiratory syncytial virus infectious disease Ablynx, a Sanofi company Withdrawn No outcome recorded
Phase 2 NCT03418571 Mar → Oct 2018 respiratory syncytial virus infectious disease Ablynx, a Sanofi company Terminated No outcome recorded
Phase 2 NCT02979431 Jan 2017 → May 2018 respiratory syncytial virus infectious disease Ablynx, a Sanofi company Completed Met primary

Evidence & citations 4 cited values

Every value below carries the sentence it was read from. 8 sources stand behind the page.

FieldValueCited text
Known as ALX 0171 “The secondary objective is to assess the clinical activity, pharmacokinetics (PK), virology, and immunogenicity of inhaled ALX 0171 in adults diagnosed with RSV respiratory...” NCT03468829 ↗
7

NCT03418571 ↗

NCT02979431 ↗

NCT01875926 ↗

NCT01483911 ↗

NCT03468829 ↗

NCT02309320 ↗

NCT01909843 ↗
Known as Gontivimab ChEMBL registry synonym — accepted as the source's own label CHEMBL4297692 ↗
Modality Protein / enzyme biologic “ALX-0171 is a Nanobody directed against the human respiratory syncytial virus (RSV).” NCT01483911 ↗
Route Inhaled “administered via pulmonary inhalation” NCT01483911 ↗